{
    "id": "63f043e4f36125a426000023",
    "question": "Is Baricitinib effective for Alopecia Areata?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"Baricitinib has demonstrated effectiveness in promoting hair regrowth among adults with severe alopecia areata. Clinical trials have shown promising results for the use of baricitinib in the treatment of alopecia areata. Following successful outcomes in clinical trials, baricitinib has received FDA approval for treating severe alopecia areata in adults. Therefore, the answer is yes, Baricitinib is effective for Alopecia Areata.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "article-132927_9",
            "title": "Baricitinib -- Mechanism of Action",
            "content": "The pathogenesis of alopecia areata is attributed to a combination of genetic factors and immune dysregulation. Essential cytokines, such as interferon-\u03b3 and interleukin-15, are involved in the disease process, relying on JAKs for intracellular signaling. Baricitinib has demonstrated effectiveness in promoting hair regrowth among adults with severe alopecia areata. [12]"
        },
        {
            "id": "article-132927_4",
            "title": "Baricitinib -- Indications -- FDA-Approved Indications",
            "content": "In 2020, following a clinical trial, the FDA also granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized patients who need supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). [3] Subsequently, the EUA was revised to authorize baricitinib as a standalone treatment for adult patients. However, for pediatric patients aged 2 to 17, baricitinib continues to be under EUA status. [4] Clinical trials have shown promising results for the use of baricitinib in the treatment of alopecia areata. [2] Following successful outcomes in clinical trials BRAVE-AA1 and BRAVE-AA2, baricitinib has received FDA approval for treating severe alopecia areata in adults. [5]"
        },
        {
            "id": "article-17385_30",
            "title": "Alopecia Areata -- Treatment / Management -- Immunotherapy and JAK Inhibitors",
            "content": "Oral ritlecitinib, an inhibitor of JAK3 and the tyrosine kinase expressed in the hepatocellular carcinoma kinase family, is approved by the\u00a0FDA for patients aged 12 and older with alopecia areata. Similar to baricitinib, continued use is likely necessary to maintain the effects. The initial dose is 50 mg/d. Potential adverse effects are increased risk for severe infection, death, malignancy, lymphoproliferative disorders, major adverse cardiovascular events, thromboembolic events, and hematologic, hepatic, and creatine phosphokinase laboratory abnormalities."
        },
        {
            "id": "article-132927_23",
            "title": "Baricitinib -- Adverse Effects",
            "content": "Baricitinib is generally considered a safe and well-tolerated medication. However, it increases the risk of severe infections due to its immunosuppressive properties. During clinical trials, the most frequently reported adverse events in alopecia areata patients included upper respiratory tract infections, acne vulgaris, headaches, urinary tract infections, and folliculitis. [5] [18] In addition, there is an increased incidence of herpes zoster infections."
        },
        {
            "id": "article-17384_54",
            "title": "Alopecia -- Treatment / Management -- Alopecia areata",
            "content": "Other therapeutic options include topical sensitization with diphenylcyclopropenone (DPCP) or anthralin and methotrexate with or without oral corticosteroids. [6] Also, the U. Food and Drug Administration recently approved the JAK inhibitor baricitinib to treat adult patients with severe alopecia areata. Pediatric patients with a few alopecic patches can be managed by watchful waiting because up to 50% demonstrate spontaneous regrowth within\u00a06 to 12 months of onset. Topical corticosteroids can be used in patients younger than 10, intralesional steroid injections for those older than 10, and systemic corticosteroids for alopecia areata refractory to other local treatments. [5] Nonsteroidal treatments include topical immunotherapy with DPCP or anthralin and methotrexate as an adjunctive treatment for severe disease in patients\u00a0older than 12 when standard therapies have failed. [6]"
        },
        {
            "id": "article-132927_17",
            "title": "Baricitinib -- Administration -- Adult Dosage",
            "content": "Alopecia areata: The recommended initial dosage of baricitinib is 2 mg orally once daily. If there is an inadequate treatment response, the dosage may be increased to 4 mg once daily. In cases where patients exhibit complete scalp hair loss, with or without significant eyelash or eyebrow hair loss, treatment with 4 mg of baricitinib once daily, with or without food, should be considered. After achieving an adequate response to 4 mg of baricitinib, the dosage should be reduced to 2 mg once daily."
        },
        {
            "id": "article-132927_20",
            "title": "Baricitinib -- Administration -- Specific Patient Populations",
            "content": "Dosage modifications for patients with alopecia areata and renal impairment are as follows: For mild renal impairment (eGFR: 60\u00a0to <90 mL/min/1.73 m\u00b2), no dosage adjustment of baricitinib is necessary. For moderate renal impairment (eGFR: 30\u00a0to <60 mL/min/1.73 m\u00b2), the baricitinib dose should be reduced to half. If the patient previously received 4 mg of baricitinib, the dose should be decreased to 2 mg. Similarly, if the patient was once on 2 mg of baricitinib, the dose should be further reduced to 1 mg. For severe renal impairment (eGFR: <30 mL/min/1.73 m\u00b2), baricitinib use is not recommended. Pregnancy considerations: Healthcare providers recommend discontinuing baricitinib at least one month before conception. The use of baricitinib during human pregnancy is not well-studied."
        },
        {
            "id": "article-132927_41",
            "title": "Baricitinib -- Monitoring",
            "content": "In rheumatoid arthritis, treatment response can be assessed through the Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), and the American College of Rheumatology (ACR) response criteria (ACR20, ACR50, and ACR70).\u00a0For alopecia areata, improvement in the Severity of Alopecia Tool (SALT) score is a valuable indicator for assessing treatment response. [5]"
        },
        {
            "id": "article-17385_29",
            "title": "Alopecia Areata -- Treatment / Management -- Immunotherapy and JAK Inhibitors",
            "content": "Oral baricitinib, a selective and reversible JAK1 and JAK2 inhibitor, treats alopecia areata by suppressing the activation of T lymphocytes. Patients typically require ongoing therapy to sustain the benefits achieved. The United States Food and Drug Administration (FDA) has issued a boxed warning for JAK inhibitors, cautioning about the risk of severe infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Initial dosing is 2 mg/d with an increase to 4 mg/d if the response is inadequate after 3 months. Patients with severe symptoms may start at the 4 mg/d dose. Upon achieving an adequate response, clinicians reduce the dose to 2 mg. Therapy is discontinued if no improvement is observed after 6 months."
        },
        {
            "id": "article-132927_18",
            "title": "Baricitinib -- Administration -- Specific Patient Populations",
            "content": "Hepatic impairment: For alopecia areata and rheumatoid arthritis, no dosage adjustment is required for mild-to-moderate hepatic impairment. However, its use is not recommended in cases of severe impairment for both conditions. Regarding COVID-19, baricitinib does not require dosage adjustment in mild-to-moderate hepatic impairment. However, in patients with severe hepatic impairment, its usage should be considered cautiously, with a thorough assessment of the potential benefits and risks. [15] Renal impairment: Dosage modifications for renal\u00a0impairment may vary depending on the condition being treated."
        },
        {
            "id": "article-132927_0",
            "title": "Baricitinib -- Continuing Education Activity",
            "content": "Baricitinib is a disease-modifying antirheumatic drug (DMARD) indicated for rheumatoid arthritis when conventional DMARDs prove inadequate. This medication is approved by the U.S. Food and Drug Administration (FDA)\u00a0to treat adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to other DMARDs, including tumor necrosis factor antagonist therapies.\u00a0Furthermore, baricitinib is FDA-approved for treating COVID-19, presenting a valuable choice in combination with other therapies for hospitalized patients, including pediatric cases necessitating supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. This activity comprehensively reviews\u00a0the indications, contraindications, mechanisms, adverse events, and other crucial aspects of baricitinib therapy within the clinical setting. This activity is tailored to meet the specific needs of an interprofessional healthcare team responsible for treating patients with rheumatoid arthritis, alopecia areata, and COVID-19."
        },
        {
            "id": "article-17385_43",
            "title": "Alopecia Areata -- Enhancing Healthcare Team Outcomes",
            "content": "Comprehensive care for patients with alopecia areata involves addressing both the psychosocial and physical aspects, along with monitoring for associated illnesses. Various healthcare specialties, including primary care, dermatology, rheumatology, and endocrinology, frequently encounter patients with alopecia areata. To effectively care for these individuals, healthcare professionals must possess essential knowledge for diagnosis and management, understand potential treatment adverse effects, and recognize the psychosocial impact of alopecia areata. In addition, clinicians must remain vigilant for associated dermatologic and systemic illnesses, ensuring seamless interprofessional communication of specialty opinions and relevant test results."
        },
        {
            "id": "article-17387_22",
            "title": "Alopecia Totalis -- Treatment / Management -- JAK Inhibitors",
            "content": "JAK inhibitors are newer medications that are currently being studied in alopecia areata and totalis. These include tofacitinib, ruxolitinib, and baricitinib. These agents have promising therapeutic benefits due to our current understanding of the pathogenesis of AA. JAK inhibitors have proven efficacious in treating other inflammatory conditions such as rheumatoid arthritis and psoriasis. There are a few open-label trials for AA patients, which have shown impressive results with significant hair regrowth. However, many patients have a recurrence of hair loss after therapy discontinuation. Side effects of oral JAK inhibitors include viral reactivation, infection, transaminitis, and bone marrow suppression. [12] JAK inhibitors have also been used topically. [18] Topical 2% tofacitinib has been reported to have good results, though relapse upon discontinuation is also high. [21]"
        },
        {
            "id": "article-17384_58",
            "title": "Alopecia -- Differential Diagnosis",
            "content": "Various subtypes of alopecia are confused with each other and require detailed examination through dermoscopy and biopsy. Some of the differentials\u00a0include: Androgenetic alopecia: Alopecia areata, telogen effluvium, traction alopecia, trichotillomania, FFA, LPP, and central centrifugal cicatricial alopecia [1] Alopecia areata: Tinea capitis, trichotillomania, and temporal triangular alopecia for patchy alopecia areata and female-pattern hair loss, telogen effluvium, and drug-induced alopecia for diffuse forms of alopecia areata [6] Telogen effluvium: Androgenetic alopecia and diffuse forms of alopecia areata [44] FFA and LPP: Chronic cutaneous lupus erythematosus, central centrifugal cicatricial alopecia, and folliculitis decalvans [45]"
        },
        {
            "id": "article-17384_53",
            "title": "Alopecia -- Treatment / Management -- Alopecia areata",
            "content": "Alopecia areata therapies \"aim to immunosuppress or immunomodulate the activity of the disease.\" [6] The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata was published in 2020. [41] Topical corticosteroids are recommended as a first-line therapy for treating limited patchy alopecia areata and adjunctive therapy in more severe forms. Intralesional corticosteroid injections are also a first-line recommendation for limited patchy alopecia areata, alone or combined with topical corticosteroids. The preferred corticosteroid is triamcinolone acetonide. Oral corticosteroids can be used as first-line treatment for moderate-to-severe disease (SALT score >30%) in adults, alone or combined with topical corticosteroids. [41]"
        },
        {
            "id": "article-17385_2",
            "title": "Alopecia Areata -- Continuing Education Activity",
            "content": "Objectives: Identify the clinical manifestations and characteristic features of alopecia areata for accurate diagnosis. Screen patients for signs and symptoms indicative of alopecia areata during routine examinations. Implement evidence-based treatment strategies based on the severity and extent of hair loss in patients with alopecia areata. Collaborate with interprofessional healthcare providers to coordinate care and provide holistic support to patients with alopecia areata by addressing both physical and psychosocial needs. Access free multiple choice questions on this topic."
        },
        {
            "id": "article-17385_13",
            "title": "Alopecia Areata -- History and Physical",
            "content": "Alopecia areata usually presents as localized patches of hair loss on the scalp that emerge over a few weeks. However, this condition can also affect other areas, such as the beard, eyebrows, eyelashes, and extremities (see Image. Alopecia Areata Hair Loss). During active disease, exclamation-mark hairs, characterized by a narrower proximal end than the distal end, are commonly observed at the periphery of lesions and are a pathognomonic finding in patients with alopecia areata. [1] In a minority of cases, patients may progress to total hair loss on the scalp, known as alopecia areata totalis. Furthermore, some individuals may experience complete hair loss across the entire body, termed alopecia universalis. The various patterns of alopecia areata are: Ophiasis pattern:\u00a0Hair loss affecting the occipital region. Sisaipho (or ophiasis inversus) pattern:\u00a0Hair loss involving the frontal, temporal, and parietal scalp but spares the occipital region."
        },
        {
            "id": "article-17385_4",
            "title": "Alopecia Areata -- Introduction",
            "content": "Alopecia areata usually presents as localized patches of hair loss on the scalp, which develop over a few weeks (see Image. Alopecia Areata).\u00a0The classic presentation of alopecia areata involves isolated, smooth, sudden, nonscarring, and patchy hair loss on the scalp or any area with hair growth. [2] Although many individuals experience spontaneous hair regrowth within 1 year, alopecia areata is a chronic condition characterized by recurring episodes of hair loss\u00a0that require both psychological support and medical treatment.\u00a0Various treatment options, such as corticosteroids, immunotherapy, Janus kinase (JAK) inhibitors, and topical solutions, are available to help manage the extent and duration of hair loss."
        },
        {
            "id": "article-17385_7",
            "title": "Alopecia Areata -- Epidemiology",
            "content": "The lifetime risk of developing alopecia areata in the general population is estimated\u00a0at 2%, with a prevalence of approximately 1 in 1000. [3] [4] Although data indicate no demonstrable sex predilection, alopecia areata occurs more often among Asian, Black, and Hispanic patients. Alopecia areata affects children and adults, and the incidence rises steadily with age. The mean age at onset is 32 for males and 36 for females. [5]"
        },
        {
            "id": "article-17385_16",
            "title": "Alopecia Areata -- History and Physical",
            "content": "Approximately 10% to 15% of patients with alopecia areata experience nail involvement, characterized by fine nail pitting, trachyonychia, onychorrhexis, red spotting on the lunulae, onycholysis, and onychomadesis (see Image. Alopecia Areata Dystrophic Nails). White hair is often spared, initially giving patients the appearance of rapid greying. In addition, individuals with alopecia areata also have an elevated risk of developing conditions such as retinal detachment, retinal vein occlusion, and retinopathy. [11]"
        },
        {
            "id": "article-17384_6",
            "title": "Alopecia -- Etiology -- Alopecia areata",
            "content": "Alopecia areata is a chronic immune-mediated disease commonly presenting as acute onset patchy hair loss on the scalp, affecting both sexes and children, adolescents, and adults (see Image. Alopecia Areata). Rarely do patients present with total scalp hair loss ( alopecia totalis )\u00a0or hair over the entire body (alopecia universalis). Patients may experience a single episode or a pattern of remission and recurrence. [3] [4] [5] [6]"
        },
        {
            "id": "article-17384_34",
            "title": "Alopecia -- History and Physical -- Alopecia areata",
            "content": "Alopecia areata commonly presents with patchy hair loss on the scalp (see Image. Alopecia Areata Hair Loss);\u00a0less commonly, the conditions presents with total scalp hair loss (alopecia totalis) or complete loss of all body hair (alopecia universalis). The skin within the alopecic area(s) is smooth and intact without scarring or signs of inflammation. The hair-pull test is performed at the border of a patchy lesion and the contralateral clinically unaffected side. A positive test indicates active disease, and a negative test indicates the disease is stable or resolving. A positive pull test on the clinically unaffected side may indicate disease progression toward alopecia totalis. Dermoscopy will likely show vellus hairs (associated with remission or long-standing disease), broken hairs, black dots, and yellow dots. Exclamation mark hairs, usually seen in the periphery of active lesions, are pathognomonic for alopecia areata. Nail pitting and, in severe cases, trachyonychia (rough, longitudinally ridged nails) may be seen. [5] [6]"
        },
        {
            "id": "article-17385_34",
            "title": "Alopecia Areata -- Differential Diagnosis",
            "content": "Specific medical conditions that may be mistaken for alopecia areata include androgenetic alopecia, traction alopecia, trichotillomania, tinea capitis, secondary syphilis, aplasia cutis, and temporal triangular alopecia."
        },
        {
            "id": "article-17387_3",
            "title": "Alopecia Totalis -- Introduction",
            "content": "Alopecia areata (AA) is a chronic, autoimmune disorder of nonscarring hair loss mediated by T-lymphocytes against the hair follicular unit (see Image .\u00a0Alopecia Areata, Localized Hair Loss). [1] The most common form of disease manifests as smooth, discrete, round patches of hair loss and can be referred to as alopecia areata focalis (AF). Alopecia totalis (AT) is a more extensive subtype of AA characterized by complete loss of hair on the scalp. [2] When there is a total loss of scalp and body hair, it is called alopecia universalis (AU). Compared to focal AA, patients with AT have a poorer prognosis for hair regrowth and are more likely to have treatment failure (see Image. Alopecia Totalis With Regrowth). [3]"
        },
        {
            "id": "article-17385_39",
            "title": "Alopecia Areata -- Deterrence and Patient Education",
            "content": "Although alopecia areata is not a life-threatening condition, its psychosocial impact can be significant. Seeking emotional support from a psychologist, psychiatric provider, or support group can be beneficial. In addition, resources are available through the National Alopecia Areata Foundation's website at https://www.naaf.org/ ."
        },
        {
            "id": "article-22481_9",
            "title": "Anatomy, Hair -- Clinical Significance",
            "content": "Alopecia describes complete hair loss. This can occur on the entire scalp (alopecia totalis) or body (alopecia universalis) or may be localized to specific areas (alopecia areata). Alopecia areata can progress to alopecia totalis and often begins acutely and spreads gradually over the course of\u00a0weeks to months. Alopecia is an autoimmune disease mediated by T lymphocytes and other immune cells."
        },
        {
            "id": "article-17385_1",
            "title": "Alopecia Areata -- Continuing Education Activity",
            "content": "Although many individuals experience spontaneous hair regrowth within 1 year, alopecia areata is a chronic condition characterized by recurring episodes of hair loss that require both psychological support and medical treatment. Various treatment options, such as corticosteroids, immunotherapy, Janus kinase (JAK) inhibitors, and topical solutions, are available to help manage the extent and duration of hair loss.\u00a0This activity helps clinicians acquire proficiency in selecting and using diverse treatment modalities for patients with alopecia areata. This activity also provides\u00a0pertinent knowledge to interprofessional healthcare teams to foster improved clinician-patient interactions by emphasizing mutual collaboration and holistic management. This approach leads to well-informed treatment decisions, enhanced patient outcomes, and improved quality of life for individuals with alopecia areata."
        },
        {
            "id": "article-17385_3",
            "title": "Alopecia Areata -- Introduction",
            "content": "Alopecia areata is a chronic, immune-mediated autoimmune disorder that affects hair follicles, nails, and, occasionally, the retinal pigment epithelium. [1] This condition targets the anagen hair follicles of individuals and leads to hair loss without permanent damage to the follicles.\u00a0Alopecia areata\u00a0arises from an autoimmune disruption in the normal hair cycle, resulting in the loss of immune privilege in the hair follicles."
        },
        {
            "id": "article-17385_8",
            "title": "Alopecia Areata -- Epidemiology",
            "content": "Studies reveal that dermatologic and systemic conditions associated with alopecia areata include vitiligo, lupus erythematosus, psoriasis, atopic dermatitis, thyroid disease, and allergic rhinitis. [6] Patients with\u00a0Down syndrome (trisomy 21, MIM #190685) and polyglandular autoimmune syndrome type 1 (MIM #240300) have an increased risk of developing alopecia areata. [7] [8] [9]"
        },
        {
            "id": "article-17385_33",
            "title": "Alopecia Areata -- Treatment / Management -- Additional Therapies",
            "content": "Currently, effective topical therapies for eyelashes are lacking. However, some individuals may observe improvement with systemic therapy. Patients may explore the option of using false eyelashes. Other cosmetic alternatives include tattooed eyebrows, wigs, hairpieces, and head shaving. Alopecia areata can be distressing and may result in anxiety and depression for some individuals. Consulting with a psychologist or psychiatric provider may be necessary in such cases."
        },
        {
            "id": "article-17385_42",
            "title": "Alopecia Areata -- Deterrence and Patient Education",
            "content": "Alopecia areata is commonly associated with other dermatologic and systemic diseases. Patients must be educated on the symptoms of thyroid disease, systemic lupus erythematosus, psoriasis, and atopic dermatitis and report any symptoms they experience. Healthcare professionals treating patients with Down syndrome and polyglandular autoimmune syndrome type 1 should be vigilant due to the heightened risk of alopecia areata and should monitor for any signs of patchy hair loss."
        },
        {
            "id": "article-17384_20",
            "title": "Alopecia -- Pathophysiology -- Alopecia areata",
            "content": "Alopecia areata is a chronic immune-mediated disease characterized by acute or chronic hair loss, with the anagen phase of the hair growth cycle significantly shortened during acute flares. Although the exact pathophysiology is not fully understood, the collapse of the immune privilege (IP) that usually protects the hair follicle bulb plays an important role. [16] Interferon-gamma and substance P are potent inducers of the collapse secondary to increasing proinflammatory factors while decreasing IP guardians. [17] Interleukin (IL)-2 and IL-15 have also been implicated as important mediators capable of inducing a topical immune reaction in alopecia areata. [6]"
        }
    ],
    "scores": [
        17.1737003326416,
        15.974599838256836,
        15.3681001663208,
        14.473400115966797,
        14.282600402832031,
        13.965100288391113,
        13.711799621582031,
        13.260000228881836,
        12.975600242614746,
        12.785099983215332,
        12.715999603271484,
        12.64210033416748,
        12.193599700927734,
        12.158300399780273,
        11.946000099182129,
        11.775500297546387,
        11.753399848937988,
        11.536499977111816,
        11.48330020904541,
        11.397000312805176,
        11.351900100708008,
        11.184599876403809,
        11.137700080871582,
        11.080300331115723,
        11.06309986114502,
        10.96090030670166,
        10.957599639892578,
        10.92140007019043,
        10.921399116516113,
        10.863900184631348,
        10.783300399780273,
        10.725799560546875
    ]
}